FDA review of drug names
This article was originally published in The Tan Sheet
Executive Summary
Drug Safety & Risk Management Advisory Committee will convene Dec. 4 to "discuss current screening methods to assess sound alike and look alike proprietary drug names, in order to reduce the incidence of medication errors." Meeting, previously scheduled for Sept. 18-19, was postponed for weather-related reasons. Session will follow-up on topics explored at a June meeting co-sponsored by FDA, PhRMA and the Institute for Safe Medication Practices (1"The Tan Sheet July 7, 2003, p. 12). Panel will meet at the Holiday Inn in Gaithersburg, from 8 am to 5 pm...
You may also be interested in...
Drug Names Tentatively Accepted As Trademarks Could Be Placed On Internet
FDA is thinking of making tentatively accepted drug trade names viewable on the Internet
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.